Stay updated on Regorafenib after Sorafenib for Hepatocellular Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Regorafenib after Sorafenib for Hepatocellular Carcinoma Clinical Trial page.

Latest updates to the Regorafenib after Sorafenib for Hepatocellular Carcinoma Clinical Trial page
- Check6 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe study location entry was updated from Padua, Veneto, Italy, 35128 to Padova, Veneto, Italy, 35128.SummaryDifference0.0%

- Check35 days agoChange DetectedAdded Hepatocellular carcinoma as the condition, included the Genetic and Rare Diseases Information Center as a resource, and updated the location entry from Napoli to Naples, Campania, Italy (80131) with revision to v3.5.0.SummaryDifference0.1%

- Check49 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3. No study content or usability aspects appear to be affected.SummaryDifference0.0%

- Check64 days agoChange DetectedRemoved the sponsor link 'Click here to find results for studies related to Bayer Healthcare products' from the Bayer Helpful Links section. This change does not affect the core study details, eligibility criteria, or outcomes presented on the page.SummaryDifference0.0%

- Check71 days agoChange DetectedMinor site revision updated from v3.4.1 to v3.4.2 with no changes to study content or user-facing features. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Regorafenib after Sorafenib for Hepatocellular Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Regorafenib after Sorafenib for Hepatocellular Carcinoma Clinical Trial page.